StockMirror — Stock Screener

VIMTALABS Q2 FY27 Results & Earnings Analysis

Sentiment: Neutral (Confidence: high)

Earnings Summary

Vimta Labs reported a steady Q2 FY27 with ~10% YoY revenue growth to INR 1,149 million and a PAT of INR 206 million, up 3.5% YoY . However, revenue was flat sequentially, which management attributed to longer customer decision cycles in pharma R&D and a sharp decline in export-linked food testing. Despite near-term headwinds, the long-term outlook remains highly confident, underpinned by strong industry tailwinds in pharma, electronics, and EVs, and the company's diversified service portfolio. Management reiterated its medium-term target of ~20-25% revenue growth and reaching ~INR 700 crores by FY28 . Key strategic initiatives include the ramp-up of the new biologics CRADS business and expanding preclinical capabilities . While the core business remains profitable, a shift in service mix towards biologics may cause a 100-200 bps correction in EBITDA margins in the medium term .

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

The management is focused on translating its strong capabilities into stronger revenue momentum while sustaining profitability . They are confident in their ability to achieve medium-term growth targets (20-25% CAGR) while maintaining or slightly expanding margins . However, they also acknowledge a

About Vimta Labs Limited

Vimta Labs Limited (VIMTALABS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More